Asthma Therapeutics Market Growth Accelerates to 20.4 Billion USD By Key Innovative Product Development Strategies, Top Key Players, Size Estimations and Future Trends Analysis By 2026

The Global Asthma Therapeutics Market, by Drug Class (Corticosteroids, Beta2-Agonists (Long-acting and Short-acting), Leukotriene Inhibitors, Long-acting Muscarinic Antagonists (LAMA), Interleukin Antagonists, Anti-immunoglobulin E (IgE) Agents, Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids, and Others), and Others), By Route of Administration (Oral, Inhalation, and Injection), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ XX million in 2017, and is projected to exhibit a CAGR of 1.9%, during the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.

Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-sample/2698

An inhaler is a medical device that facilitates the delivery of the drug through the lungs and into the body. It is mostly used to treat respiratory disorders and diseases such as asthma and chronic obstructive pulmonary disease (COPD). It is divided into two types; dry powder inhaler and metered-dose inhaler also named as aerosol-based inhalers. Dry powder inhalers are an alternative to metered-dose-inhalers. Therefore, increasing approval for inhalers by regulatory authorities is expected to drive the global asthma therapeutics market growth. For instance, in January 2019, Teva Pharmaceuticals Industries received the U.S. Food and Drug Administration (USFDA) approval for its new (ProAir Digihaler) digital Inhaler that is used to improve and treat diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD). ProAir Digihaler is the first digital inhaler. It is a multi-dose dry powder inhaler which delivers 117 µg of Albuterol. Moreover, the rising number of clinical trials of asthma treatment is expected to boost the value of the global asthma therapeutics market. For instance, in May 2018, Montefiore Medical Center initiated a clinical study to evaluate the performance of ‘Adapting and Expanding the Algorithmic Software Tool (ASTHMAXcel App)’. This software teaches the fundamental concept of asthma and its management. The study was started in May 2018 and expected to complete in April 2020.

Browse 23 Market Data Tables and 19 Figures spread through 157 Pages and in-depth TOC on “Asthma Therapeutics  Market, by Drug Class (Corticosteroids, Beta2-Agonists (Long-Acting and Short-Acting), Leukotriene Inhibitors, Long-Acting Muscarinic Antagonists (LAMA), Interleukin Antagonists, Anti-Immunoglobulin E (IgE) Agents, Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids, and Others), and Others), by Route of Administration (Oral, Inhalation, and Injection), and by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2026” To know the latest trends and insights related to Global Asthma Therapeutics Market Press Release, click the link below: https://www.coherentmarketinsights.com/press-release/asthma-therapeutics-market-to-surpass-us-204-billion-by-2026-1426

Several key players are focusing on launching new products in the market for asthma treatment. For instance, in May 2019, FindAir Company launched its new Smart Inhaler Device FindAir One in Europe. It is used for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Furthermore, in January 2019, FindAir One received CE marking for distribution in Europe. Additionally, stable research and development activities are expected to drive the development of the global asthma therapeutics market. For instance, in March 2018, Interregional Public Organization and Russian Respiratory Society initiated a clinical study to collect anonymous long-term evidence of severe asthma patients in Russia. The study is expected to complete in December 2022. Moreover, the University of Chicago initiated a phase II clinical study on Azithromycin for treatment of asthma in February 2019 and it is expected to complete in February 2020.

Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2698

Key Takeaways of the Global Asthma Therapeutics Market:

• The global asthma therapeutics market is expected to witness a CAGR of 1.9% during the forecast period (2018–2026) due to product launches to improve respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The global asthma therapeutics market is also expected to surpass US$ 20.4 billion by 2026.
• North America is expected hold the largest market share in the global asthma therapeutics market over the forecast period (2018–2026) due to the increasing prevalence of respiratory diseases in the U.S. For instance, according to the Centers for Disease Control and Prevention (CDC), around 24 million people, including over 6 million children, suffered from asthma in the U.S in 2016.
• Major players operating in the global asthma therapeutics market are GlaxoSmithKline Plc., Philips Healthcare, AstraZeneca, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sanofi-Aventis SA, CareFusion Corporation, Sunovion Pharmaceuticals, Inc. Merck & Co., Inc., and Roche Diagnostics.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.